t
Arecor Therapeutics plc and Sequel Med Tech LLC will host a virtual fireside panel discussion. The event is scheduled for Wednesday, 7 January 2026, at 16:00 GMT, and no new material information will be disclosed.
| Date | 6 Jan 2026 |
| Time | 14:01:10 |
| Category | Miscellaneous |
| ID | 8671N |
Arecor Therapeutics plc
("Arecor" or the "Company")
Arecor and Sequel Med Tech virtual fireside panel discussion
Cambridge, UK, 6 January 2026: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, and Sequel Med Tech LLC ("Sequel"), a company developing state-of-the-art insulin delivery technologies, will be hosting a virtual fireside panel discussion on the future of the treatment journey for people with diabetes and factors driving diabetes innovation, on Wednesday 7 January 2026 at 16:00 GMT / 11:00 ET / 08:00 PT.
At this event, no new material information will be disclosed.
To register for the event, please email [email protected] or [email protected].
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
+44 (0) 1223 426060 |
|
|
|
|
Singer Capital Markets Advisory LLP |
+44 (0) 20 7496 3000 |
|
Phil Davies, Andrew Johnson, James Todd |
|
|
|
|
|
Vigo Consulting (IR and PR for Arecor) |
+44 (0) 20 7390 0230 |
|
|
|
|
Sequel Med Tech LLC Gabby Fernandes, VP, Finance & Investor Relations
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.
Arecor® and Arestat® are registered trademarks of Arecor Limited.
About Sequel Med Tech
Headquartered in Manchester, New Hampshire, US, Sequel is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at diabetes management holistically to advance systems that make living with diabetes simpler and easier for all. Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel's focus is to bring the latest developments in science and technology to the marketplace, helping drive more accessible drug delivery. For more information, please visit www.sequelmedtech.com.